NOVO.B.DK

445.8

+3.24%↑

GMAB.DK

1,297

-0.19%↓

HLUNB.DK

35.98

+0.39%↑

ZEAL.DK

358.7

+0.03%↑

AMBUB.DK

100.2

+3.14%↑

NOVO.B.DK

445.8

+3.24%↑

GMAB.DK

1,297

-0.19%↓

HLUNB.DK

35.98

+0.39%↑

ZEAL.DK

358.7

+0.03%↑

AMBUB.DK

100.2

+3.14%↑

NOVO.B.DK

445.8

+3.24%↑

GMAB.DK

1,297

-0.19%↓

HLUNB.DK

35.98

+0.39%↑

ZEAL.DK

358.7

+0.03%↑

AMBUB.DK

100.2

+3.14%↑

NOVO.B.DK

445.8

+3.24%↑

GMAB.DK

1,297

-0.19%↓

HLUNB.DK

35.98

+0.39%↑

ZEAL.DK

358.7

+0.03%↑

AMBUB.DK

100.2

+3.14%↑

NOVO.B.DK

445.8

+3.24%↑

GMAB.DK

1,297

-0.19%↓

HLUNB.DK

35.98

+0.39%↑

ZEAL.DK

358.7

+0.03%↑

AMBUB.DK

100.2

+3.14%↑

Search

Coloplast A-S (Class B)

Open

604.8 3.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

583.2

Max

608.2

Belangrijke statistieken

By Trading Economics

Inkomsten

-132M

912M

Verkoop

-96M

6.9B

K/W

Sectorgemiddelde

29.529

40.527

EPS

5.45

Dividendrendement

3.66

Winstmarge

13.16

Werknemers

16,741

EBITDA

2.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+11.86% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.66%

2.40%

Volgende Winsten

19 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-23B

134B

Vorige openingsprijs

601.7

Vorige sluitingsprijs

604.8

Coloplast A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 jul 2025, 23:09 UTC

Winsten

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 jul 2025, 19:16 UTC

Acquisities, Fusies, Overnames

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 jul 2025, 23:47 UTC

Marktinformatie

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 jul 2025, 23:41 UTC

Marktinformatie

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 jul 2025, 22:23 UTC

Acquisities, Fusies, Overnames

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 jul 2025, 22:23 UTC

Acquisities, Fusies, Overnames

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 jul 2025, 22:21 UTC

Acquisities, Fusies, Overnames

James Hardie Completes Acquisition of AZEK

1 jul 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 jul 2025, 20:24 UTC

Winsten

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 jul 2025, 19:55 UTC

Marktinformatie

Oil Futures Resume Cautious Rally -- Market Talk

1 jul 2025, 19:27 UTC

Marktinformatie

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 jul 2025, 19:12 UTC

Marktinformatie

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 jul 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 jul 2025, 18:41 UTC

Acquisities, Fusies, Overnames

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 jul 2025, 18:33 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

1 jul 2025, 18:33 UTC

Marktinformatie

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 jul 2025, 18:32 UTC

Marktinformatie

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 jul 2025, 18:22 UTC

Marktinformatie

Remittances to Mexico Down in May -- Market Talk

1 jul 2025, 17:45 UTC

Marktinformatie

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 jul 2025, 17:01 UTC

Acquisities, Fusies, Overnames

Danone Completed Acquisition of Majority Stake in Kate Farms

1 jul 2025, 16:55 UTC

Winsten

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 jul 2025, 16:27 UTC

Marktinformatie

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 jul 2025, 16:25 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 jul 2025, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jul 2025, 15:48 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 jul 2025, 15:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

1 jul 2025, 15:46 UTC

Marktinformatie

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 jul 2025, 14:54 UTC

Marktinformatie

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 jul 2025, 14:49 UTC

Marktinformatie

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer Vergelijking

Prijswijziging

Coloplast A-S (Class B) Prognose

Koersdoel

By TipRanks

11.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 901.38 DKK  11.86%

Hoogste 1,056 DKK

Laagste 720 DKK

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Coloplast A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

2

Buy

4

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.